Abstract
This group of syndromes shares severe insulin resistance and hyperinsulinemia with variable clinical manifestations.1,2 Attention has been paid to these rare disorders because they provide insight into several aspects of insulin action at the molecular level and advance our understanding of the more common insulin resistant disorders, such as polycystic ovarian syndrome3 and type 2 diabetes mellitus.4
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kahn CR, Flier JS, Bar RS, et al. The syndrome of insulin resistance and acanthosis nigricans: insulin receptor disorders in man. N Engl J Med; 294: 739–745, 1976.
Moller DE, Flier JS. Insulin resistance: Mechanisms, syndromes, and implications. N Eng J Med; 325: 938–948, 1991.
Barbieri RL, Smith S, Ryan KJ, et al. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 50: 197–212, 1988.
Barroso I, Curnell M, Crowley VE, et al. Dominant negative mutation in human PPAR gamma associated with severe insulin resistance, diabetes mellitus, and hypertension. Nature 402: 880–883, 1999.
Collinet M, Berthelon M, Benit P, et al. Familial hyperinsulinemia due to a mutation substituting histidine for arginine at position 65 in proinsulin: identification of the mutation by restriction enzyme mapping. Eur J Pediatr 157: 450–460, 1998.
Hanede M, Polonsky KS, Bergenstal RM, et al. Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Eng J Med 310: 1288–1294, 1984.
Duckworth WC, Bennet RG, Hamel FG. Insulin degradation: Progress and potential. Endo Rev 19: 608–624, 1998.
Francis A, Hanning I, Alberti KG. The influence of insulin antibody levels on the plasma profile and action of subcutaneously injected human and bovine short acting insulins. Diabetologia 28: 330–334, 1985.
Taylor SI, Grunberger G, Marcus-Samuels B, et al. Hypoglycemia associated with antibodies to the insulin receptor. N Eng J Med 307: 1422–1426, 1982.
Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103: 931–943, 1999.
Gorden P, Carpentier JL, Frechet PO, et al. Internalization of polypeptide hormones: mechanism, intracellular localization and significance. Diabetologia 18: 263–274, 1980.
Grunberger G, Robert A, Carpentier JL, et al. Human circulating monocytes internalize 125I-insulin in a similar fashion to rat hepatocytes: relevance to receptor regulation in target and non-target tissue. J Lab Clin Med. 106: 211–217, 1985.
Flier JS, Minaker KL, Landsburg L, et al. Impaired in vivo insulin clearance in patients with target cell resistance to insulin. Diabetes 31: 132–135, 1982.
Flier JS. Metabolic importance of acanthosis nigricans. Arch Derm 121: 193–194, 1985.
Cruz PD, Hud JA Jr. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 98 (suppl): 82S - 85S, 1992.
Fradkin JE, Eastman RC, Lesniak MA, et al. Specificity spillover at the hormone receptor: exploring its role in human disease. N Engl J Med; 320: 640–645, 1989.
Rotman-Pikielny P, Andewelt A, Ozyavuzligil A, et al. Polycystic ovarian syndrome (PCOS): Lessons from patients with severe insulin resistance syndromes. The Endocrine Society’s 83`d Annual Meeting p80, 2001.
Cauble MS, Gilroy R, Sorrel MF, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 71: 892–895, 2001.
Garg A, Wilson R, Barnes R, et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab 84: 3390–3394, 1999.
Peters JM, Barnes R, Bennett L, et al. Localization the gene for familial partial lipodystrophy (Dunnigan Variety) to chromosome 1q21–22. Nat Genet 18: 292–295, 1998.
Jackson SN, Pinkney J, Bargiotta A, et al. A defect in the regional deposition of adipose tissue (partial lipodystrophy) is encoded by a gene at chromosome lq. Am J Hum Genet 63: 534–540, 1998.
Cao H, Hegele RA. Nuclear lamin A/ C R482Q mutations in Canadian kindreds with Dunnigan type familial partial lipodystophy. Hum Molec Genet 9: 109–112, 2000.
Billings JK, Milgraum SS, Gupta AK, et al. Lipoatrophic panniculitis: a possible autoimmune inflammatory disease of fat report of three cases. Arch Dermatol 123: 1662–1666, 1987.
Hubler A, Abendroth K, Keiner T, et al. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence syndrome) connected with autoantibodies against adipocytes membranes. Exp Clin Endocrinol Diabetes 106: 79–84, 1998.
Mathieson PW, Wurzner R, Oliveria DB, et al. Complement mediated adipocytes lysis by nephritic factor sera. J Exp Med 177: 1827–1831, 1993.
Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy. A 5-year cohort study. Arch Int Med 160: 2050–2056, 2000.
Van Der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse trancriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 15: 847–855, 2001.
Panse I, Vasseur E, Raffin-Sanson ML, et al. Lipodystrophy associated with protease inhibitors. Br J Dermatol 142: 496–500, 2000.
Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein —1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50: 1378–1388, 2001.
Dowell P, Flexner C, Kwiterovich PO, et al. Suppression of preadipocyte differentiation and promotion of adipocytes death by HIV protease inhibitors. J Biol Chem 275: 41325–41332, 2000.
Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275: 2025120254, 2000.
Meyer MM, Schuett M, Jost P, et al. Indinavir decreases insulin-stimulated phosphatidylinositol 3-kinase activity and stimulates leptin secretion in human adipocytes. Diabetes 50 (Suppl 2): A414, 2001.
Flier JS, Moller DE, Moses AC, et al. Insulin—mediated pseudoacromegaly: Clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 76: 1533–1541, 1993.
Martin XD, Zenobi PD. Type A syndrome of insulin resistance: anterior chamber anomalies of the eye and effects of insulin — like growth factor-1 on the retina. Ophthalmologica 215: 117–123, 2001.
Grunberger G, Zick Y, Gorden P. Defect in phosphorylation of insulin receptors in cells from an insulin-resistant patient with normal insulin binding. Science 223: 832–934, 1984.
Maddux BA, Goldfine ID. Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with receptor alpha subunit. Diabetes 49: 13–19, 2000.
Flier JS, Kahn CR, Roth J, et al. Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 190: 63–65, 1975.
Arioglu E, Andewelt A, Diabo C, et al. Clinical course of autoantibody to the insulin receptor syndrome. The Endocrine Society’s 83`d Annual Meeting p113, 2001.
Flier JS, Bar RS, Muggeo M, et al. The evolving clinical course of patients with insulin receptor autoantibodies: Spontaneous remission or receptor proliferation with hypoglycemia. J Clin Endocrinol Metab 47: 985–995, 1978.
Bar RS, Levis WR, Rechler MM, et al. Extreme insulin resistance in ataxia telangectasia: defect in affinity of insulin receptors. NEngl J Med 298: 1164–1171, 1978.
Burant CF, Sreenan S, Hirano K, et al. Troglitazone action is independent of adipose tissue. J Clin Invest 100: 2900–2908, 1997.
Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndrome. Ann Int Med 133: 263–274, 2000.
Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome. JAMA 284: 472–477, 2000.
Di Paolo S. Metformin ameliorates extreme insulin resistance in a patient with anti-insulin receptor antibodies: Description of insulin receptor and postreceptor effects in vivo and vitro. Acta Endocrinol 126: 117–123, 1992.
Rique S, Ibanez L, Marcos MV, et al. Effect of metformin on androgen and insulin concentration in type A insulin resistance syndrome. Diabetologia 43: 385–386, 2000.
Nakae J, Kato M, Murashita M, et al. Long-term effect of recombinant human insulin — like growth factorl on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab 83: 542–549, 1998.
Morrow LA, O’Brien MB, Moller DE, et al. Recombinant human insulin like growth factor —1 therapy improves glycemic control and insulin action in type A syndrome insulin resistance. J Clin Endocrinol Metabol 79: 205–210, 1994.
Quin JD, Fisher BM, Paterson KR, et al. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall’s syndrome. N Engl J Med 323: 1425–1426, 1990.
Yamamoto T, Sato T, Mori T, et al. Clinical efficacy of insulin like growth factor 1 in a patient with auto-antibodies to insulin receptors: A case report. Diabetes Res Clin Pract 49: 65–69, 2000.
Torres RA, Unger KW, Cadman JA, et al. Recombinant human growth hormone improves truncal adiposity and buffalo humps in HIV positive patients on HAART. AIDS 13: 2479–2481, 1999.
Kramer N, Rosenstein ED, Schneider G. Refractory hyperglycemia complicating an evolving connective tissue disease: response to cyclosporin. J Rheumatol 25: 816–818, 1998.
Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipotrophic mice. J Clin Invest 105: 271–278, 2000.
Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401: 73–76, 1999.
Reitman ML, Gavrilova O. A-ZIP/F-1 mice lacking white fat: a model for understanding lipoatrophic diabetes. Int J Obes Relat Metab Disord 24 (Suppl 4): S11 - S14, 2000.
Zhang B. Salituro G, Szalkowski D, et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 284: 974–977, 1999.
Eriksson JW, Bremell T, Eliasson B, et al. Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Case report. Diabetes Care 21: 1217 1220, 1998.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Grunberger, G., Alrefai, H. (2004). Syndromes of Extreme Insulin Resistance. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6260-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4757-6260-0_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-6262-4
Online ISBN: 978-1-4757-6260-0
eBook Packages: Springer Book Archive